An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration

Jie Yang, Yingbo Li, Jiemei Sun, Hongyan Zou, Yige Sun, Jing Luo, Qian Xie, A Rong, Hongbin Wang, Xiaona Li, Kai Wang, Lili Yang, Teng Ma, Lina Wu, Xilin SunACS 2022 · DOI

Abstract

Low accumulation of anticancer drugs in tumors and serious systemic toxicity remain the main challenges to the clinical efficiency of pharmaceuticals. Pulmonary delivery of nanoscale-based drug delivery systems offered a strategy to increase antitumor activity with minimal adverse exposure. Herein, we report an osimertinib-loaded perfluoro-15-crown-5-ether (AZD9291-PFCE) nanoemulsion, through intratracheal and intravenous delivery, synergizes with <sup>19</sup>F magnetic resonance imaging (<sup>19</sup>F MRI)-guided low-intensity focused ultrasound (LIFU) for lung cancer therapy. Pulmonary delivery of AZD9291-PFCE nanoemulsion in orthotopic lung carcinoma models achieves quick distribution of the nanoemulsion in lung tissues and tumors without short-term and long-term toxic effects. Furthermore, LIFU can trigger drug release from the AZD9291-PFCE nanoemulsion and specifically increases tumor vascular and tumor tissue permeability. <sup>19</sup>F MRI was applied to quantify nanoemulsion accumulation in tumors in real time after LIFU irradiation. We validate the treatment effect of AZD9291-PFCE nanoemulsion in resected human lung cancer tissues, proving the translational potential to enhance clinical outcomes of lung cancer therapy. Thus, this work presents a promising pulmonary nanoemulsion delivery system of osimertinib (AZD9291) for targeted therapy of lung cancer without severe side effects.
BibTeX
@inproceedings{yang2022osimertinib,
  author = {Jie Yang and Yingbo Li and Jiemei Sun and Hongyan Zou and Yige Sun and Jing Luo and Qian Xie and A Rong and Hongbin Wang and Xiaona Li and Kai Wang and Lili Yang and Teng Ma and Lina Wu and Xilin Sun},
  title = {{An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration}},
  booktitle = {ACS},
  year = {2022},
  doi = {10.1021/acsnano.2c04159},
}

Loading related content...

Figure